Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Cancer Research|May 15, 1992
Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugsG Rappa, A Lorico, A C SartorelliCancer Research|October 15, 1990
Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase IIG Rappa, A Lorico, A C SartorelliCancer Research|November 15, 1993
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocinG Rappa, A Lorico, A C SartorelliInternational Journal of Cancer|July 9, 1992
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26)G Rappa, A Lorico, A C SartorelliInternational Journal of Cancer|December 2, 1992
Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cellsA Lorico, G Rappa, A C SartorelliCancer Research|December 11, 1997
Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxinsG Rappa, A Lorico, R A Flavell, et al.Human Gene Therapy|September 19, 2001
Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agentsG Rappa, A Lorico, M Hildinger, et al.Biochemical Pharmacology|July 21, 1999
New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knockout modelsG Rappa, R A Finch, A C Sartorelli, et al.Cancer Research|December 1, 1996
Double knockout of the MRP gene leads to increased drug sensitivity in vitroA Lorico, G Rappa, R A Flavell, et al.Oncology Research|February 24, 2001
Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16)G Rappa, K Shyam, A Lorico, et al.Pageof 3